Notice2022-20529
National Institute on Drug Abuse; Notice of Closed Meetings
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 22, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 183 (Thursday, September 22, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 183 (Thursday, September 22, 2022)]
[Notices]
[Pages 57918-57919]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-20529]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Accelerating the Pace of Drug Abuse Research Using
Existing Data.
Date: October 27-28, 2022.
Time: 11 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Li Rebekah Feng, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, National Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-7245,
<a href="/cdn-cgi/l/email-protection#5a283f383f313b32743c3f343d1a343332743d352c"><span class="__cf_email__" data-cfemail="beccdbdcdbd5dfd690d8dbd0d9fed0d7d690d9d1c8">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Increasing Immediate Engagement and Retention in HIV
Treatment with Substance Users.
Date: October 27, 2022.
Time: 1 p.m. to 2 p.m.
[[Page 57919]]
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Marisa Srivareerat, Ph.D., Scientific Review
Officer, Scientific Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 435-1258,
<a href="/cdn-cgi/l/email-protection#90fdf1e2f9e3f1bee3e2f9e6f1e2f5f5e2f1e4d0fef9f8bef7ffe6"><span class="__cf_email__" data-cfemail="ddb0bcafb4aebcf3aeafb4abbcafb8b8afbca99db3b4b5f3bab2ab">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Coordinating Center for the HIV/AIDS and Substance
Use Cohorts Program.
Date: November 2, 2022.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Brian Stefan Wolff, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 480-1448, <a href="/cdn-cgi/l/email-protection#3e5c4c575f501049515258587e50575610595148"><span class="__cf_email__" data-cfemail="e587978c848bcb928a898383a58b8c8dcb828a93">[email protected]</span></a>.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Avenir Award Program for Chemistry and Pharmacology
of Substance Use Disorders (DP1--Clinical Trial Allowed).
Date: November 29, 2022.
Time: 9:45 a.m. to 6 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Marisa Srivareerat, Ph.D., Scientific Review
Officer, Scientific Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 435-1258,
<a href="/cdn-cgi/l/email-protection#0a676b7863796b247978637c6b786f6f786b7e4a646362246d657c"><span class="__cf_email__" data-cfemail="9af7fbe8f3e9fbb4e9e8f3ecfbe8ffffe8fbeedaf4f3f2b4fdf5ec">[email protected]</span></a>.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: September 16, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-20529 Filed 9-21-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 22, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.